Clinico-histopathological Profile of Primary Paediatric Intra-abdominal Tumours: a Multi-hospital-Based Study

Nitin Joseph1, Sharada Rai2, Kshitiz Singhal3

  • 1Post Graduate Diploma in Family Medicine, Department of Community Medicine, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, Karnataka India.

Insights

Paediatric intra-abdominal tumours are rising in India, predominantly affecting males under 15. Wilm's tumour was most common, with fever a frequent symptom. Treatment outcomes varied by tumour type and stage.

Area of Science:

  • Oncology
  • Paediatrics
  • Epidemiology

Background:

  • Paediatric cancers represent approximately 5% of India's total cancer burden.
  • Intra-abdominal tumours are a significant proportion of childhood cancers.
  • This study analyzes demographic, clinical, and management data for paediatric intra-abdominal tumours.

Purpose of the Study:

  • To investigate the demographic profile of children with intra-abdominal tumours.
  • To describe the clinical features and management strategies employed.
  • To identify factors influencing treatment outcomes and remission rates.

Main Methods:

  • Retrospective analysis of histopathologically confirmed paediatric intra-abdominal tumours (2009-2019).
  • Inclusion criteria: patients aged <15 years with primary intra-abdominal tumours.
  • Data collected on demographics, clinical presentation, treatment, and outcomes.

Main Results:

  • 50 patients included; median age 3 years; 70% male.
  • Wilm's tumour was the most frequent (34%), with 96% of tumours being malignant.
  • Fever (54%) was common; Vincristine was the most used drug. Remission rates were higher for Wilm's tumour and Hodgkin's lymphoma. Stage 4 malignancy correlated with treatment default, while germ cell tumours showed better recovery.

Conclusions:

  • Intra-abdominal tumours in children are predominantly malignant, with Wilm's tumour being the most common.
  • Treatment response varies significantly by tumour type and stage.
  • Further research is needed to understand and address treatment default in advanced-stage paediatric malignancies.